CD4 and cancer: Thus, this study suggests that (I) systemic induction of helper CD4+ T cells and (II) reprogramming of hematopoiesis and manipulation of the precursor pool might be essential for effective cancer therapy and that (III) analysis of the blood immune cell pool might serve as biomarker for the efficacy of cancer treatments [357].